Construction of stabilized and tagged foot-and-mouth disease virus

Park, Jeong-Nam; Ko, Mi-Kyeong; Kim, Rae-Hyung; Park, Min-Eun; Lee, Seo-Yong; Yoon, Jiwon; Choi, Joo-Hyung; You, Su-Hwa; Park, Jung-Won; Lee, Kwang‐Nyeong; Chun, Ji-Eun; Kim, Su-Mi; Tark, Dongseob; Lee, Hyang-Sim; Ko, Young-Joon; Lee, Myoung-Heon

doi:10.1016/j.jviromet.2016.09.013

Cited by 5 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 3 mg/dose of ribavirin or 6-azauridine was injected IP twice per day from day 0 to day 3. A 3 mg/dose of T1105 was injected IP at 0, 8, 13, 24, and 30 h. Six hours after the agent was first administered, the mice (n = 5 per group) were IP inoculated with 50 LD 50 (50% lethal dose) Asia1 Shamir [ 24 ]. In addition, as a positive control, intramuscular inoculation of recombinant adenovirus Ad-3siRNA expressing three siRNAs against FMDV and Ad-IFN-αγ of 5 × 10 8 TCID 50 expressing concurrently IFN-α and IFN-γ [ 14 ], these were injected 1 day before the mouse challenge.…”

Section: Methodsmentioning

confidence: 99%

Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease

et al. 2018

Self Cite

View full text Add to dashboard Cite

In many countries, vaccines are used for the prevention of foot-and-mouth disease (FMD). However, because there is no protection against FMD immediately after vaccination, research and development on antiviral agents is being conducted to induce protection until immunological competence is produced. This study tested whether well-known chemicals used as RNA virus treatment agents had inhibitory effects on FMD viruses (FMDVs) and demonstrated that ribavirin showed antiviral effects against FMDV in vitro/in vivo. In addition, it was observed that combining the administration of the antiviral agents orally and complementary therapy with vaccines synergistically enhanced antiviral activity and preserved the survival rate and body weight in the experimental animals. Antiviral agents mixed with an adjuvant were inoculated intramuscularly along with the vaccines, thereby inhibiting virus replication after injection and verifying that it was possible to induce early protection against viral infection prior to immunity being achieved through the vaccine. Finally, pigs treated with antiviral agents and vaccines showed no clinical signs and had low virus excretion. Based on these results, it is expected that this combined approach could be a therapeutic and preventive treatment for early protection against FMD.

show abstract

Section: Methodsmentioning

confidence: 99%

Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is continuous development of new vaccines but it is labor and difficult to develop a new vaccine whenever a new virus appears [52,53,54]. Therefore, many kinds of research have been conducted to develop advanced vaccines that can respond to evolving versions of the virus [55,56]. Current problems with FMD vaccines include antigens losses during the process of purification, unable to maintain the antibodies, low immunogenicity and narrow protection range of the antigens [57].…”

Section: De-population Of Infected Animalsmentioning

confidence: 99%

A review on foot and mouth disease in dairy animals, etiology, pathogenesis and clinical findings

Azeem¹

2020

PAB

View full text Add to dashboard Cite

Foot-and-mouth disease (FMD) is an extremely contagious disease of angulated animals and in livestock, it is an important pathogen more than 120 years after it was recognized. The virus of this disease belong to a genus Aphthovirus of the family picornaviridae and present as seven serotypes C, O, A, SAT1, SAT2, SAT3, and Asia1. Transmission of this disease occurs by direct and indirect contact, ingestion and by aerosols. The best multiplication sites of this virus are oral cavity, udder, heart, feet, and oro-pharynx. Specific, sensitive and quick diagnostic tools are required for effective control of this disease. FMD causes fever, salivation, anorexia and vesicular eruption on teats, feet, and mouth. In FMDV (Foot and Mouth disease Virus) endemic areas, annual production losses and vaccination estimated US$6.5-US$21 billion. Currently, the techniques which are used for diagnosis of FMD are Sandwich-ELISA (S-ELISA), Virus Isolation (VI), indirect ELISA (DIVA), real time-PCR and Liquid-Phase Blocking ELISA (LPBE) can be used for recognition of antibody against nonstructural proteins. The techniques which are used for quick and specific detection of FMDV are microarray and recombinant antigen-based detection, biosensor, Nucleotide sequencing, phage display and nucleic-acid-based diagnostic for serotyping. This review provides information about the FMD in Pakistan as many cases are reported in Pakistan and lead to morbidity and mortality of many animals. This review helps the reader to handle the cases practically in the field and helps the researchers to analyze the comprehensive picture of the FMD and in future researchers try to minimize such cases after reading this in Pakistan.

show abstract

Preserved immunogenicity of an inactivated vaccine based on foot-and-mouth disease virus particles with improved stability

Caridi

Vázquez-Calvo

Borrego

et al. 2017

Veterinary Microbiology

View full text Add to dashboard Cite

Construction of stabilized and tagged foot-and-mouth disease virus

Cited by 5 publications

References 29 publications

Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease

Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease

A review on foot and mouth disease in dairy animals, etiology, pathogenesis and clinical findings

Preserved immunogenicity of an inactivated vaccine based on foot-and-mouth disease virus particles with improved stability

Contact Info

Product

Resources

About